NASDAQ:CTOR
Citius Oncology, Inc.
Citius Oncology, Inc. reported net income of −$24.8M in fiscal 2025. The diluted share count rose 7.7%.Summary generated from Citius Oncology, Inc.'s SEC filings. Latest annual report filed Dec 23, 2025.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−54.4%
Debt / equityn/a
Free cash flown/a
FCF marginn/a
Share count change+7.7%
Financials
| Item | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | n/a | n/a | n/a |
| Operating income | n/a | −21 | −24 |
| Net income | −13 | −21 | −25 |
| Free cash flow | n/a | n/a | n/a |
Recent filings
- 8-KResults of a shareholder vote
Sep 29, 2026 - DEF 14AProxy statement
Aug 26, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 14, 2026 - 8-KResults of operations and financial condition
Aug 14, 2026 - 8-KDirector or officer change
Aug 12, 2026 - 8-KOther events
Aug 5, 2026 - 8-KOther events
Jun 1, 2026 - 8-KResults of operations and financial condition
May 15, 2026